Allarity Therapeutics, Inc. (ALLR) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The Phase II study, titled “Phase II, Open Label, Single Arm Study to Investigate Anti-tumor Effect of Ixabepilone in Patients With Locally Recurrent or Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP After Failure of an Anthracycline and Taxanes,” tested whether a drug-response test could improve outcomes for hard-to-treat metastatic breast cancer. It focused on patients who had already failed standard drugs and aimed to show if a targeted selection tool could deliver meaningful tumor control.
The study used ixabepilone injection, a chemotherapy drug given by IV on the first day of a 3 week cycle. The goal was to match this treatment to patients most likely to benefit, using Allarity’s DRP test as a selection tool.
The trial followed a simple single arm design, where all patients received ixabepilone and there was no randomization or placebo group. It was open label, so doctors and patients knew which treatment was used, and the main goal was treatment effect, measured by tumor response and clinical benefit.
The trial was first submitted in March 2021, marking the formal start of the clinical plan and signaling early development risk for investors. Results were first submitted in February 2026, and the record was last updated in March 2026, which is important because the study is now listed as terminated, meaning it stopped early and will not move forward as originally planned.
From a market view, the termination reduces the near term value of this specific program for Allarity Therapeutics, Inc. (ALLR) and may weigh on sentiment around its DRP platform. Investors will likely compare these results with other precision oncology players and larger breast cancer drug makers, and may shift attention toward companies with later stage assets or stronger confirmatory data.
The study has been terminated and is now updated on the ClinicalTrials portal, where investors can find further details on design, endpoints, and posted results.
To learn more about ALLR’s potential, visit the Allarity Therapeutics, Inc. drug pipeline page.